{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-032573","form_type":"8-K","ticker":"BIXT","cik":"0001445815","company_name":"BIOXYTRAN, INC","filed_at":"2022-11-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.691777+00:00","generated_at":"2026-06-21T17:24:18.121847+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Bioxytran Phase 2 trial of ProLectin-M shows 100% viral clearance at day 7 in COVID-19 patients","bullets":["100% of treated patients achieved viral clearance by day 7 vs 6% placebo (p=.001); 88% by day 3 vs 0% placebo.","No drug-related serious adverse events or viral rebounds during 14-day observation period.","NMR data show ProLectin-M binds galectin-3 with micromolar affinity (2 μM) and blocks S1 subunit and ACE2 receptors.","Results provide rationale for upcoming Phase 2/3 registrational trial.","Company plans to explore the galectin antagonist platform for other viruses and indications."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-032573","json":"https://secwatch.observer/filing/0001493152-22-032573.json","markdown":"https://secwatch.observer/filing/0001493152-22-032573.md","text":"https://secwatch.observer/filing/0001493152-22-032573.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445815/000149315222032573/0001493152-22-032573-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445815/000149315222032573/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T17:24:18.121847+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}